Discovery and In Vivo Efficacy of AZ-PRMT5i-1, a Novel PRMT5 Inhibitor with High MTA Cooperativity.

已完结 10 由杨小木发布于 2024/8/21 18:01:01

DOI:10.1021/acs.jmedchem.4c00097
作者：James M Smith, Bernard Barlaam, David Beattie, Lauren Bradshaw, Ho Man Chan, Elisabetta Chiarparin, Olga Collingwood, Sophie L Cooke, Anna Cronin, Iain Cumming, Emma Dean, Judit É Debreczeni, Iván Del Barco Barrantes, Coura Diene, Davide Gianni, Carine Guerot, Xiaoxiao Guo, Sinem Guven, Thomas G Hayhow, Ted Hong, Paul D Kemmitt, Gillian M Lamont, Scott Lamont, James T Lynch, Lisa McWilliams, Shaun Moore, Piotr Raubo, Graeme R Robb, James Robinson, James S Scott, Bharath Srinivasan, Oliver Steward, Christopher J Stubbs, Karl Syson, Lixiang Tan, Oliver Turner, Elizabeth Underwood, Jelena Urosevic, Mercedes Vazquez-Chantada, Amy L Whittaker, David M Wilson, Jon J Winter-Holt
文献类型：期刊论文
补充材料：只需要正文

American Chemical Society (ACS)

Abstract：PRMT5, a type 2 arginine methyltransferase, has a critical role in regulating cell growth and survival in cancer. With the aim of developing MTA-cooperative PRMT5 inhibitors suitable for MTA

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:其它数据库Targeted and Efficient Delivery of siRNA Using Tunable Polymeric Hybrid Micelles for Tumor Therapy.